CCR 20(th) Anniversary Commentary: Simpson’s Paradox and Neoadjuvant Trials

Por Carey, Lisa A.
Publicado no Clin Cancer Res (2015)

Understanding and Treating Triple-Negative Breast Cancer

Por ANDERS, CAREY, CAREY, LISA A.
Publicado em 2008

Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

Por Anders, Carey K., Carey, Lisa A.
Publicado em 2009

PARP and Cancer — If It's Broke, Don't Fix It

Por Carey, Lisa A., Sharpless, Norman E.
Publicado em 2011

Understanding how breast cancer patients use risk information from genomic tests

Por DeFrank, Jessica T, Carey, Lisa A, Brewer, Noel T
Publicado em 2012

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

Por Mayer, Erica L, Carey, Lisa A, Burstein, Harold J
Publicado em 2007

The Management of Early Stage and Metastatic Triple Negative Breast Cancer: A Review

Por Anders, Carey K., Zagar, Timothy M., Carey, Lisa A.
Publicado em 2013

Disparities in Breast Cancer Treatment and Outcomes: Biological, Social, and Health System Determinants and Opportunities for Research

Por Wheeler, Stephanie B., Reeder-Hayes, Katherine E., Carey, Lisa A.
Publicado em 2013

Improving Communication of Breast Cancer Recurrence Risk

Por Brewer, Noel T., Richman, Alice R., DeFrank, Jessica T., Reyna, Valerie F., Carey, Lisa A.
Publicado em 2011

The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies

Por Barry, William T., Perou, Charles M., Marcom, P. Kelly, Carey, Lisa A., Ibrahim, Joseph G.
Publicado no J Biopharm Stat (2015)

Disparities in Use of Human Epidermal Growth Hormone Receptor 2–Targeted Therapy for Early-Stage Breast Cancer

Por Reeder-Hayes, Katherine, Peacock Hinton, Sharon, Meng, Ke, Carey, Lisa A., Dusetzina, Stacie B.
Publicado no J Clin Oncol (2016)

Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation

Por Jordan, Jennifer J., Inga, Alberto, Conway, Kathleen, Edmiston, Sharon, Carey, Lisa A., Wu, Lin, Resnick, Michael A.
Publicado em 2010

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

Por Fan, Cheng, Prat, Aleix, Parker, Joel S, Liu, Yufeng, Carey, Lisa A, Troester, Melissa A, Perou, Charles M
Publicado em 2011

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

Por Prat, Aleix, Adamo, Barbara, Cheang, Maggie C.U., Anders, Carey K., Carey, Lisa A., Perou, Charles M.
Publicado em 2013

Prognostic B-Cell Signatures using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer

Por Iglesia, Michael D., Vincent, Benjamin G., Parker, Joel S., Hoadley, Katherine, Carey, Lisa A., Perou, Charles M., Serody, Jonathan S.
Publicado em 2014

Tumor Therapeutic Response and Vessel Tortuosity: Preliminary Report in Metastatic Breast Cancer

Por Bullitt, Elizabeth, Lin, Nancy U., Ewend, Matthew G., Zeng, Donglin, Winer, Eric P., Carey, Lisa A., Smith, J. Keith
Publicado em 2006

PARP Inhibition: “Targeted” Therapy for Triple Negative Breast Cancer

Por Anders, Carey K., Winer, Eric P., Ford, James M., Dent, Rebecca, Silver, Daniel P., Sledge, George W., Carey, Lisa A.
Publicado em 2010

Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?

Por Anders, Carey K., Fan, Cheng, Parker, Joel S., Carey, Lisa A., Blackwell, Kimberly L., Klauber-DeMore, Nancy, Perou, Charles M.
Publicado em 2011

Engaging in Health Behaviors to Lower Risk for Breast Cancer Recurrence

Por O'Neill, Suzanne C., DeFrank, Jessica T., Vegella, Patti, Richman, Alice R., Henry, Leonard R., Carey, Lisa A., Brewer, Noel T.
Publicado em 2013

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer

Por Prat, Aleix, Carey, Lisa A., Adamo, Barbara, Vidal, Maria, Tabernero, Josep, Cortés, Javier, Parker, Joel S., Perou, Charles M., Baselga, José
Publicado em 2014